EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study

Jolien Van den Bossche, Maxime De Laere iD, Koen Deschepper, Paul Germonpré, Yvan Valcke, Jan Lamont, Barbara Stein, Kirsten Van Camp, Charlotte Germonpré, Griet Nijs, Ella Roelant, Sébastien Anguille und 2 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307204 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2024. Verfasst von Jolien Van den Bossche und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cell Therapy and Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Cancer Vaccines, Dendritic Cells. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kom op tegen Kanker, Roche, Methusalem financing program of the Flemish Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing standard-of-care treatment for several malignancies, including MPM. As multiple arguments and accumulating lines of evidence are in support of the existence of a therapeutic synergism between chemotherapy and immunotherapy, as well as between different classes of immunotherapeutics, we designed a multicenter, single-arm, phase I/II trial in which both programmed-death-ligand 1 (PD-L1) inhibition and dendritic cell (DC) vaccination are integrated in the first-line conventional platinum/pemetrexed-based treatment scheme for epithelioid MPM patients (Immuno-MESODEC, ClinicalTrials.gov identifier NCT05765084). Fifteen treatment-naïve patients with unresectable epithelioid subtype MPM will be treated with four 3-weekly (±3 days) chemo-immunotherapy cycles. Standard-of-care chemotherapy consisting of cisplatinum (75mg/m 2 ) and pemetrexed (500mg/m 2 ) will be supplemented with the anti-PD-L1 antibody atezolizumab (1200 mg) and autologous Wilms’ tumor 1 mRNA-electroporated dendritic cell (WT1/DC) vaccination (8–10 x 10 6 cells/vaccination). Additional atezolizumab (1680 mg) doses and/or WT1/DC vaccinations (8–10 x 10 6 cells/vaccination) can be administered optionally following completion of the chemo-immunotherapy scheme. Follow-up of patients will last for up to 90 days after final atezolizumab administration and/or WT1/DC vaccination or 24 months after diagnosis, whichever occurs later. The trial’s primary endpoints are safety and feasibility, secondary endpoints are clinical efficacy and immunogenicity. This phase I/II trial will evaluate whether addition of atezolizumab and WT1/DC vaccination to frontline standard-of-care chemotherapy for the treatment of epithelioid MPM is feasible and safe. If so, this novel combination strategy should be further investigated as a promising advanced treatment option for this hard-to-treat cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedB7-H1 AntigenCancer VaccinesDendritic CellsMesothelioma, MalignantAdultAgedFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsMesotheliomaPemetrexedPleural NeoplasmsVaccinationWT1 ProteinsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicMulticenter Studies as Topic

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenCancer VaccinesCD274 protein, humanCisplatinImmune Checkpoint InhibitorsPemetrexedWT1 protein, humanWT1 Proteins

Autor:innen und Institutionen

  • Center for Cell Therapy and Regenerative Medicine (CCRG), Antwerp University Hospital (UZA), Edegem, Belgium.
  • Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Division of Pulmonary and Infectious Diseases, VITAZ, Sint-Niklaas, Belgium.
  • Respiratory Oncology & Integrated Cancer Cancer Ghent, AZ Maria Middelares, Ghent, Belgium.
  • Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital (UZA), University of Antwerp, Edegem, Belgium.
  • Division of Hematology, Antwerp University Hospital (UZA), Edegem, Belgium.

ORCID-Profile: Maxime De Laere

Förderung

  • Kom op tegen Kanker
  • Roche
  • Methusalem financing program of the Flemish Government
  • UZA Foundation

Zitieren

APA

Van den Bossche, J., De Laere, M., Deschepper, K., Germonpré, P., Valcke, Y., Lamont, J., Stein, B., Van Camp, K., Germonpré, C., Nijs, G., Roelant, E., Anguille, S., Lion, E., & Berneman, Z. (2024). Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study. PLOS ONE. https://doi.org/10.1371/journal.pone.0307204

Vancouver

Van den Bossche J, De Laere M, Deschepper K, Germonpré P, Valcke Y, Lamont J, et al. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study. PLOS ONE. 2024. doi:10.1371/journal.pone.0307204

BibTeX
@article{VandenBossche2024,
  author = {Van den Bossche, Jolien and De Laere, Maxime and Deschepper, Koen and Germonpré, Paul and Valcke, Yvan and Lamont, Jan and Stein, Barbara and Van Camp, Kirsten and Germonpré, Charlotte and Nijs, Griet and Roelant, Ella and Anguille, Sébastien and Lion, Eva and Berneman, Zwi},
  title = {Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307204}
}
Kostenlos starten →